Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.49 |
| ▸ | CCR4 | P51679 | 2/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | DUT | P33316 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23568845 | 0.81 | CCR4 (0.40) | PTGES2CCR4CA12CA1CA2 | |
| SCHEMBL1510259 | 0.81 | FBP1 (0.48) | PTGES2CCR4ACLYCA12CA1 | |
| SCHEMBL15881105 | 0.80 | ACLY (0.49) | PTGES2CCR4ACLYKITCA1 | |
| SCHEMBL6261295 | 0.80 | PTGES2 (0.53) | PTGES2CCR4ACLYKITCCR1 | |
| SCHEMBL14544512 | 0.77 | PTGES2 (0.41) | PTGES2CCR4ACLYKITCCR1 | |
| SCHEMBL21612293 | 0.76 | ACLY (0.49) | PTGES2CCR4ACLYLGALS8LGALS3 | |
| SCHEMBL20680912 | 0.74 | PTGES2 (0.45) | PTGES2CCR4ACLYKITCCR1 | |
| SCHEMBL14014135 | 0.74 | CDK1 (0.60) | PTGES2CCR4ACLYKITCA12 | |
| SCHEMBL742144 | 0.74 | PTGES2 (0.42) | PTGES2CCR4ACLYKITCCR1 | |
| SCHEMBL7589854 | 0.73 | PTGES2 (0.61) | PTGES2CCR4ACLYKITCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1887008-B1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-2544535-B1 | PHENOXY THIOPHENE SULFONAMIDES AND THEIR USE AS INHIBITORS OF GLUCURONIDASE | NORTH CAROLINA CENTRAL UNIV (US) | 2017-04-19 | — | — | EP | disclosed |
| US-8044042-B2 | Thienotriazolodiazepine compound and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044042-B2 | Thienotriazolodiazepine compound and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | ICOS, CD4, CD2 | PTGES2 1418/4885CCR4 254/4885ACLY 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.